View Older Stories View More Recent Stories
-
Elevance Health (ELV) Securities Fraud: Contact Berger Montague To Discuss Your Rights
-
ELV SHAREHOLDER ALERT: BFA Law Reminds Elevance Health, Inc. Investors with Losses of the Imminent July 11 Legal Deadline
-
ELV SHAREHOLDERS: Investors with Losses on Elevance Health, Inc. are Notified to Contact BFA Law prior to the July 11 Class Action Deadline
-
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Elevance Health (ELV)
-
Elevance Health, Inc. (ELV) Investors with Losses are Notified to Contact BFA Law before the Upcoming July 11 Class Action Deadline
-
ELV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elevance Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ELV
-
Elevance Health (ELV) call put ratio 1.2 calls to 1 put as share price down 3.4%
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elevance Health
-
Bernstein: 'We See the Reaction to PBM Stocks as Off Target'
-
ELV LEGAL NOTICE: Elevance Health, Inc. Investors with Losses are Reminded to Contact BFA Law by July 11 Class Action Deadline
-
United States Files False Claims Act Complaint Against Three National Health Insurance Companies and Three Brokers
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
Bernstein Reiterates Outperform on Elevance (ELV); 'Strong Growth in Carelon'
-
Elevance Health Inc. (ELV) Tops Q1 EPS by 89c
-
Elevance Health (ELV) call put ratio 1 call to 2 puts with a focus on May calls
-
Elevance Health (ELV) calls more active than puts into quarter results
-
Elevance Health (ELV) call put ratio 1.5 calls to 1 put as share price down 1.9%
-
Elevance Health (ELV) intends to reaffirm adjusted net income guidance
-
Guggenheim Starts Elevance (ELV) at Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
Given contract opportunity Caid stocks likely undervalued, says Cantor Fitzgerald
-
Elevance (ELV) PT Raised to $585 at Bernstein on 'Multiple Paths to Improving EPS Growth'
-
BofA Positive on UnitedHealth Group (UNH) and CVS (CVS) Reserves Positions, Negative on Humana (HUM)
-
Bernstein on Value Based Care Sector: 'We See an Attractive Set Up'
-
Elevance (ELV) PT Raised to $450 at Argus, Upgrades to Buy
-
Elevance Health (ELV) to reaffirm earnings guidance
-
Humana (HUM) Trades Lower in Sympathy with UnitedHealth Group (UNH)
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
These stocks will come under pressure as Republicans ready to deliver Medicaid cuts
-
Elevance Health (ELV) call put ratio 1 call to 1 put as Trump administration pauses assistance program payouts
-
Elevance (ELV) PT Lowered to $479 at JPMorgan
-
Elevance (ELV) PT Raised to $511 at Bernstein Following a 'Stable Quarter'
-
Cantor Fitzgerald Reiterates Underweight Rating on Elevance (ELV)
-
Elevance Health Inc. (ELV) Misses Q4 EPS by 14c; offers guidance
-
Elevance Health (ELV) call put ratio 1.9 calls to 1 put into quarter results
-
Elevance Health (ELV) call put ratio 1.5 calls to 1 put into quarter results
-
Humana (HUM), Others Gain After Proposal Could Lead to Increased Payments from MA Plans
-
Bernstein Comments on Senators' Proposal to Break Up PBMs; UNH, CVS, CI Stocks Down 5-6%
-
Elevance Health (ELV) call put ratio 1.1 calls to 1 put as share price down 1.9%
-
Elevance Health (ELV) call put ratio 1 call to 1 put as share price up 2.9%
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Trump picks RFK Jr for HHS — Here are potential policy implications
-
UnitedHealth Group (UNH), Humana (HUM) gain as Bernstein says Trump win positive for MCOs
-
Elevance (ELV) PT Lowered to $548 at JPMorgan
-
Elevance (ELV) PT Lowered to $484 at TD Cowen
-
Elevance (ELV) PT Lowered to $529 at Jefferies
-
Elevance (ELV) PT Lowered to $515 at Leerink Partners
-
Elevance (ELV) PT Lowered to $520 at Truist Securities
-
Elevance (ELV) PT Lowered to $478 at RBC Capital

